Immunotherapy Treatment Shows Promise for Triple Negative Breast Cancer
The addition of neoadjuvant pembrolizumab to chemotherapy reduced triple negative breast cancer recurrence by more than a third, trial results suggested.
United Kingdom City Of Peter Schmid Queen Mary University Of London Drug Administration National Institute For Clinical Excellence
Source: medscape.com